Question

Poor prognostic marker in MM is

• A. S. creatinine
• B. Hypercalcemia
• C. B2 microglobulins
• D. Telomerase

Answer 1

The Correct Option is C

In the context of multiple myeloma (MM), prognostic markers are factors that can predict the likely progression of the disease and help guide treatment decisions. Among the options provided, B2 microglobulins is known to be a poor prognostic marker. Elevated levels of B2 microglobulins in the blood are associated with a higher tumor burden and a poorer prognosis in MM patients.

Here's a brief explanation of each option:

1. S. creatinine: This is used to assess kidney function. While renal impairment can occur in MM, S. creatinine is more an indicator of kidney involvement rather than a direct prognostic marker.
2. Hypercalcemia: This condition results from increased calcium levels, often due to bone degradation. Although it indicates disease activity, it is not specifically used as a prognostic marker in MM.
3. B2 microglobulins: High levels of B2 microglobulins correlate with a poorer prognosis. They reflect tumor burden and kidney function impair, hence its integration in staging systems for MM.
4. Telomerase: Typically involved in cellular aging and cancer biology, telomerase is not specifically used as a prognostic marker in multiple myeloma.

Therefore, among the options, B2 microglobulins is the correct answer as a poor prognostic marker in multiple myeloma.